Drinking 3 to 4 cups of coffee per day may decrease endometrial cancer risk by nearly 20%
the ONA take:
According to a new study published in the journal Cancer Epidemiology, Biomarkers & Prevention, researchers from Imperial College London in London, United Kingdom, have found that drinking three to four cups of coffee per day may reduce a woman's risk of developing endometrial cancer by nearly a fifth.
For the study, researchers sought to investigate how dietary factors influence the risk of developing endometrial cancer. They analyzed data from 1,303 women with endometrial cancer who participated in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
In that study, participants completed questionnaires about their dietary habits. Results showed that butter, carbohydrates, cheese, coffee, monounsaturated fats, phosphorous, potatoes, and total fat may be associated with risk of endometrial cancer.
Then, researchers analyzed data from 1,531 women with endometrial cancer who participated in the Nurses' Health Study (NHS) or Nurses' Health Study II (NHSII), in which participants also completed dietary questionnaires. The team next looked at the association between the nine foods identified in the EPIC study and risk of endometrial cancer in the NHS and NHSII studies.
They found that drinking three cups of coffee per day decreased endometrial cancer risk by 19% among those in the EPIC study compared with those who drank less than one cup per day.
In addition, the team found that women who drank four cups per day reduced endometrial cancer risk by 18% versus those who never drank coffee in the NHS and NHSII studies.
Drinking three to four cups of coffee per day may reduce a woman's risk of developing endometrial cancer by nearly a fifth.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|